Indivior PLC (IZQVF) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 North Chesterfield, VA, 미국. 현재 CEO는 Mark Crossley.
IZQVF 을(를) 보유 IPO 날짜 2014-12-26, 1,000 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $2.89B.
Indivior PLC is a specialty pharmaceutical company that develops, manufactures, and markets buprenorphine-based prescription medications for treating opioid dependence and related disorders. The company's primary products include SUBLOCADE, an injectable formulation, and SUBOXONE, available in sublingual film and tablet forms, alongside legacy medications such as Temgesic and Buprenex. With operations spanning approximately 40 countries worldwide, Indivior focuses on addressing opioid use disorder, addiction, and co-occurring conditions through its product pipeline. Headquartered in North Chesterfield, Virginia, the company was established in 2014 and maintains research collaborations to advance its therapeutic offerings.
